Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,142 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 164 | Michael B. Atkins, MDOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07047001 | Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Dong WenOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT02446860 | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)(ADAPTeR) | terminated | Phase 2 | 15 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT03297593 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 74 | Swiss Cancer InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04337970 | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT02899078 | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 31 | University of California, DavisOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT02440334 | Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation | completed | Phase 2 | 53 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT03173560 | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | completed | Phase 2 | 343 | Eisai Inc.INDUSTRY | 16 | Apr 1, 2025 | clinicaltrials |
| NCT01147822 | Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 367 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 28, 2025 | clinicaltrials |
| NCT04267120 | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) | terminated | Phase 2 | 11 | Washington University School of MedicineOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06884683 | Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma(NivoMet) | terminated | Phase 2 | 12 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03149822 | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | terminated | Phase 2 | 16 | Incyte CorporationINDUSTRY | 5 | Mar 13, 2025 | clinicaltrials |
| NCT04495894 | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma | terminated | Phase 2 | 68 | Emory UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT01767636 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01130519 | A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer | completed | Phase 2 | 83 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT01884961 | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2(IL2HD) | completed | Phase 2 | 46 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02761057 | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 2 | Jan 13, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04068831 | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | active not recruiting | Phase 2 | 118 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06730672 | An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | terminated | Phase 2 | 3 | ImaginAb, Inc.INDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT03015740 | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02639182 | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | completed | Phase 2 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT02819596 | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma(CALYPSO) | completed | Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT03393936 | Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 66 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06648902 | Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue | completed | Phase 1 / Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 3 | Oct 18, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03109015 | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing(ASSET) | completed | Phase 2 | 7 | Duke UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 74 | X4 PharmaceuticalsINDUSTRY | 2 | Oct 3, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2025source: clinicaltrials